Charlene Liao, PhD, is co-founder, President, and Chief Executive Officer of ImmuneOnc Therapeutics. Previously, she held drug-development and business leadership roles at Genentech, where she led development efforts across the product lifecycle for ten new molecular entities. Prior to joining Genentech, Dr. Liao was a Director of Business Development at Rigel. She received her BS in biochemistry from Peking University in China and her PhD from Brandeis University in the lab of Dr. Michael Rosbach (Nobel Prize in Physiology or Medicine, 2017).
Immune-Onc Therapeutics was launched in September 2016, focusing on developing therapeutic antibodies for immune-oncology treatments. They apply the latest scientific insights and expertise in drug development to advance novel immuno-oncology products to bring new treatments to cancer patients. The lead program at Immune-Onc, an antibody targeting an immune inhibitory receptor, moves beyond T-cell targeted therapies as a potential candidate in the treatment of acute myeloid leukemia (AML) and other cancers.